Status:
COMPLETED
Metformin Versus Vildagliptin for Diabetic Hypertensive Patients
Lead Sponsor:
MTI University
Conditions:
Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients
Eligibility:
FEMALE
40-60 years
Phase:
PHASE4
Brief Summary
This is a controlled study to measure the efficacy of using metformin or vildagliptin for type 2 diabetic patients who suffers from hypertension to reduce cardiovascular risk resulting from both diabe...
Detailed Description
Several studies indicated that type 2 diabetes mellitus and hypertension are associated with increased cardiovascular complications. Recently, studies suggest that metformin and vildagliptin can reduc...
Eligibility Criteria
Inclusion
- Patients suffering from moderate HTN and DM, their HbA1c ≥ 7 and age range between 40-60 years, treatment with diet alone, any combination of oral antidiabetic agents and/or insulin before admission
Exclusion
- Clinical evidence of ischemic heart disease, chronic obstructive pulmonary disease, presence of diabetic ketoacidosis (DKA), patients admitted to intensive care unit (ICU), subjects expected to undergo surgery during the study period, patients with clinically relevant hepatic disease, impaired renal function (serum creatinine ≥3.0 mg/dL), systemic infections or pregnancy. Also, patients on medications known to interfere with the blood glucose level (either increasing or decreasing) were excluded from the study.
Key Trial Info
Start Date :
February 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2017
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03253562
Start Date
February 1 2017
End Date
August 1 2017
Last Update
August 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National institute of diabetes and endocrinology
Cairo, Egypt, 11311